infliximab + adalimumab

Infliximab and adalimumab are both tumor necrosis factor-alpha (TNF-α) inhibitors used in combination therapy for inflammatory bowel disease (IBD) and other inflammatory conditions. Both medications work by binding to TNF-α, a key proinflammatory cytokine involved in chronic inflammatory diseases, thereby blocking its interaction with receptors and reducing inflammation. While they share the same primary mechanism of action, they have structural differences - infliximab is a chimeric monoclonal antibody (75% human, 25% murine), while adalimumab is fully humanized. When used in combination, particularly with immunosuppressive drugs like azathioprine, they may provide enhanced efficacy for patients with refractory IBD.

Brand names

HumiraRemicade

Other names

anti-TNF therapy